| Name | Title | Contact Details |
|---|
Rocky Mountain Research is a Park City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
K2 Medical is a Leesburg, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bioclinica is the leader in scientifically-driven services and technology-enabled solutions in clinical research. Clinical trials are complex, and traditional approaches are either monolithic or fragmented. Successful trials require an ability to see key details and uncover hidden insights. Employing our scientifically-driven and technology-enabled approach, Bioclinica brings CLARITY to clinical trials for better decisions. With such clarity comes the insight to help trial sponsors and Clinical Research Organizations (CROs) develop new life-improving therapies more efficiently and safely ─ and with improved quality outcomes. Our scientific, medical, technology and domain expertise is unmatched and spans all major therapeutic areas ─ and the full trial lifecycle, from study protocol, to post-approval. Key offerings include: Medical imaging; Cardiac Safety; Clinical Adjudication; Randomization & Trial Supply Management and Optimization; Electronic and eSource Data Capture; Site Payments and Forecasting; Pharmacovigilance; Trial Management; and Risk-based Monitoring. Additionally, as a true multifaceted partner to trial sponsors and CROs, Bioclinica offers an integrated App xChange partner ecosystem, a global Research Network of investigative sites, Patient Recruitment and Lost to Follow-up Services, and Post-approval Research expertise. Bioclinica and our thousands of employees serve more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 biopharmaceutical companies and leading CROs – through a network of offices in the U.S., Europe, and Asia.
Max Neeman International is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.